watch
EpiStem Holdings Plc

EpiStem Holdings Plc

Sector: Medical Laboratories Region: United Kingdom


: | London Stock Exchange: EHP


Epistem is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Founded on ground-breaking research in epithelial stem cell biology, Epistem has evolved into a dynamic and successful enterprise enabling advances in medicine through the provision of innovative services and pioneering products. For over ten years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology enterprises, global pharmaceutical and personal care companies. Epistem is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Founded on ground-breaking research in epithelial stem cell biology, Epistem has evolved into a dynamic and successful enterprise enabling advances in medicine through the provision of innovative services and pioneering products. For over ten years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology enterprises, global pharmaceutical and personal care companies

Executives

David Evans, Non-Executive Chairman
David joined Epistem as a Non-executive Director in June 2005 and became Executive Chairman in March 2006 until the flotation in April 2007, when he reverted to a non-executive position.  David, a qualified accountant, has many years' experience both as an executive and as a non-executive of publicly listed diagnostic and life science companies.  In addition to his chairmanship of Epistem, he is currently Non-executive Chairman of the following AIM listed companies: EKF Diagnostics Plc, Omega Diagnostics Group Plc and Scancell Holdings Plc.
Matthew Walls, Chief Executive Officer
Matthew joined Epistem in February 2007 as Chief Executive Officer. Matthew is an experienced CEO most recently with Oxford BioSignals Limited, where he led the strategic collaboration with Rolls Royce Plc and Covance Inc.  Matthew spent the early part of his career with ICI Plc, progressing through to AstraZeneca Plc prior to its plant crop biotechnology group merger with Novartis to form Syngenta Plc.  Matthew has led the growth of several technology and biotechnology companies as CEO, including Internexus Limited and Zylepsis Limited. Matthew holds a non-executive post at Continum Limited and Riyada Oxford Investments Limited and is a chartered accountant and a member of CIMA.
John Rylands, Financial Director
John originally joined Epistem as an investor and Non-executive director, and in 2005 he took over his current role.  John provided corporate finance advice to private companies before joining Epistem. Until 1999 he was an investor in and consultant to the SDS group of companies.  John holds a degree in Economics and Accountancy from the Manchester University and is a member of ICAEW.
Allan Brown, Ph.D., Chief Operating Officer, Diagnostics Division
Allan has spent his career in the Life Sciences/diagnostics industry. During a seventeen year period with Tepnel Life Sciences plc, latterly as Divisional Managing Director, Allan's technical management roles covered product development through to commercial product launch; his commercial management roles covered sales and business development and M&A. Allan left Tepnel in 2010 following its recommended US$132m cash offer by Gen-Probe Inc. in 2009. At the time of the offer by Gen-Probe Inc. Tepnel employed over 200 employees and had operations in the UK, US, Belgium and France. After leaving Tepnel/Gen-Probe, Allan joined the leading Sample & Assay Technologies company, QIAGEN N.V., in Manchester and managed the final development and launch of the company's first US FDA approved products, helping secure the site as QIAGEN's Global Centre of Excellence for molecular diagnostic product development. Allan was appointed to the Board on 1st February, 2014.
Catherine Booth, Ph.D., Managing Director, Contract Research Services
Catherine is a co-founder of Epistem and prior to starting Epistem she worked for 10 years with Prof. Chris Potten at the Paterson Institute.  Whilst at the Paterson Institute she developed many preclinical assays.  This knowledge is at the core of the Epistem Contract Research Service.  Catherine received her Ph.D. from the Emmanuel College, University of Cambridge.
Robert Nolan, Non-executive Director
Robert has been a Non-executive Director of the Company since 2004.  He brings with him a wealth of expertise in partnering and licensing negotiations both with small biotechnology and large pharmaceutical companies. Prior to his retirement he was Director, Global Licensing at AstraZeneca.  He is also a non-executive Director of Phico Therapeutics Ltd.
Roger Lloyd, Non-executive Director
Trained as a biochemist, Roger has almost 35 years' experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development.  International business management with ICI Plc and AstraZeneca Plc included living and working in the US and Germany, and having territorial responsibilities for Europe, Japan, Korea, Mexico and the Middle East.  As Executive Director of Global Licensing at AstraZeneca, he personally completed 24 transactions, including strategic alliances with Abgenix and CAT, and acquisitions of KuDOS Pharmaceuticals and CAT.  He operates as a Board Adviser in the biotech sector.

News & Analysis